| 
Arix Bioscience PLC (ARIX)
 
 
 Arix Bioscience plc 
 Unaudited NAV for February 2023 
 LONDON, 16 March 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 28 February 2023 as follows: 
 
 
 
 [ENDS] 
 Enquiries For more information on Arix, please contact: 
 Arix Bioscience plc +44 (0)20 7290 1050 ir 
 Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson +44 (0)20 7250 1446 
 About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences. 
 We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. 
 
 Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. | ||||||||||||||||||
| ISIN: | GB00BD045071 | 
| Category Code: | MSCL | 
| TIDM: | ARIX | 
| LEI Code: | 213800OVT3AHQCXNIX43 | 
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State | 
| Sequence No.: | 230178 | 
| EQS News ID: | 1583671 | 
| End of Announcement | EQS News Service | 
|  | 
 
                     
                             
                                                                                 
                                            